Wree Alexander, Mehal Wajahat Z, Feldstein Ariel E
Department of Pediatrics, University of California San Diego (UCSD), and Rady Children's Hospital, San Diego, California.
Yale University, and West Haven Veterans Medical Center, New Haven, Connecticut.
Semin Liver Dis. 2016 Feb;36(1):27-36. doi: 10.1055/s-0035-1571272. Epub 2016 Feb 12.
Nonalcoholic fatty liver disease represents a wide spectrum of conditions and is currently the most common form of chronic liver disease affecting both adults and children in the United States and many other parts of the world. Great effort has been focused on the development of novel therapies for those patients with the more advanced forms of the disease, in particular those with nonalcoholic steatohepatitis (NASH) and liver fibrosis that can be associated with significant morbidity and mortality. In this review, the authors focus on the role of cell death and sterile inflammatory pathways as well as the self-perpetuating deleterious cycle they may trigger as novel therapeutic targets for the treatment of fibrotic NASH.
非酒精性脂肪性肝病涵盖了多种病症，目前是美国及世界许多其他地区影响成人和儿童的最常见慢性肝病形式。人们付出了巨大努力致力于为患有更晚期疾病形式的患者开发新疗法，尤其是那些患有非酒精性脂肪性肝炎（NASH）和肝纤维化的患者，这些病症可能会导致严重的发病率和死亡率。在这篇综述中，作者重点关注细胞死亡和无菌性炎症途径的作用，以及它们可能触发的自我持续有害循环，将其作为治疗纤维化NASH的新治疗靶点。
